Table II.
Highly mutated genes and their associated pathways in lung cancer
| Set | Regulatory process or pathway | Representative altered genes | Adjusted P values |
| Common | DNA damage control | TP53, MYO5A,POT1, DAXX, RB1, NBN | 2E-14 |
| c-jun N-terminal kinase signaling | TP53, DAXX, PLCB1, PIK3CG, ATF2 | 3E-21 | |
| Role of SUMO in p53 regulation | TP53, DAXX | 5E-20 | |
| Hepatocyte growth factor signaling in pancreatic cancer | TP53, HGF | 2E-18 | |
| Transforming growth factor-beta signaling | TP53, ATF2 | 5E-12 | |
| ADC | Mitogen-activated protein kinase signaling | KRAS and NOX4 | 3E-04 |
| SCC | Invasion | DDI1, PROC, MMP16, HSPA6, PCCB, LCT and AOX1 | 2E-03 |
| Small GTPase signaling | WNK1, PLCXD3, PREX2, FMN2, DAB1 and CD36 | 5E-03 | |
| ECM remodeling | LAMB1 and MMP16 | 7E-04 |